Tonix reports FY2022 net loss of $116.9M; cash $120.2M; pipeline milestones ahead

Tonix Pharmaceuticals Holding Corp.

Net loss $34.1M in Q4 2022 ($0.56/share) vs $29.6M ($2.08) in Q4 2021; FY net loss $116.9M ($3.27) vs $92.3M ($8.10).
Cash and equivalents $120.2M at Dec 31, 2022, down from $178.7M a year ago; cash used in operations $98.1M in FY2022.
Repurchased 15.7M shares under $12.5M program; new $12.5M program approved Jan 2023 with 1M shares bought.
Interim analysis for Phase 3 fibromyalgia study (TNX-102 SL) expected Q2 2023; topline Q4 2023.
Appointed R. Newcomb Stillwell to Board; acquired antiviral assets from Healion Bio; licensed monoclonal antibodies from Columbia.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Tonix Pharmaceuticals Holding Corp. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 13, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-23-003349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.